Member Info for Laura2022

17th Sept

Richard Smith, commented:

"I am honoured to join the Board at a critical juncture for RC Fornax. The Company is strongly positioned for substantial growth in response to the UK Ministry of Defence's evolving priorities.

 

"Having attended the Defence and Security Equipment International exhibition last week, one of the world's largest and most influential defence and security exhibitions, I witnessed first-hand the scale of opportunity ahead and look forward to supporting the team in delivering future success."

ALRT now £60mln cap

Puts RCFX £7mln into perspective

Thanks Ralph

Jvip

Apparently going to be a counter offer to the useless WHI board offer

Have taken some WHI at all time lows , GM 20thnOct

That 5mln ( 7%) caused the real damage , sp looks clear now

Bought at 12.69p and 13p JVIP

5mln sell is about 7%

So TR 1 due

Can still buy £15k at 12.5p

Going to wait a bit

Bottomed and upwards it goes

We continue to have productive meetings with the FDA to design the program needed to achieve marketing authorisation as a first in class (De Novo) medical device. Meanwhile, an Early Feasibility Study (EFS) previously requested by the FDA has commenced, with results expected to be available Q1 2026. Once the results of this EFS are understood, a decision will be made around the progression to and timing of a Phase 3 trial in the US which will be needed to support medical device status.

Additionally, we continue to believe that there is value in the Company's assets and therefore development plans for both Eroxon Intense and WSD4000 continue to progress. There is currently no known regulatory-approved OTC treatment available for impaired sexual response and function in women globally. We therefore see the opportunity for WSD4000 as an exciting market which we are well placed to serve, with our specialism in developing and bringing to market topically delivered gel formulations in sexual health products.

We are in the midst of a thorough strategic review to determine the best path forward. This process requires patience and care, and we appreciate the support of our investors as we take the necessary time to ensure the right long-term decisions are made. We will provide shareholders with a clear update once the review has reached its conclusion."

Shares Issued

There are 48,300,689 shares in issue as of 30 June 2025.

Significant shareholdings as of 30 June 2025:

Name Shareholding

Charles Stanley 10.59%

Close Asset Management Limited 10.40%

Mr. and Mrs. N. Slater 10.29%

Sandon Capital 8.30%

N Lawandy (Director) 8.12%

Hargreaves Lansdown PLC 6.78%

Interactive Investor 5.24%

Many thanks Amdy

Looking forward to the IMC Wednesday

The strategic rationale for developing Biometrics service capabilities was three-fold; first, the application of Modelling & Simulation and Biometrics in drug development overlaps, with the output of the former often being a key input to the latter, allowing for natural follow-on work to be offered to clients. Second, Biometrics is a necessary component of the setup, conduct and reporting of any interventional clinical trial, from Phase 1 through to Phase 4, regardless of the therapeutic area. This opens up a significant market for the Company, giving greater opportunity to scale

Andysmall

Pete is delivering well and we'll catch the current more positive biotech wave

Hopefully more on key initiatives like DoseMeRx soon also

Andy

Thankyou for that

But their final comment on Hybridan Research was " After years of growth promises these finals show genuine revenue traction which is NOT being reflected in the valuation. "

£22k buy

Moving

Oilhead

Yes, and already dropped BEFORE results so this seems a massive over rreacion

Looks like it ?